MTOR and renal cell carcinoma: Considering the high sensitivity of urinary tract tumors to programmed cell death including ferroptosis, we believe that combination of ferroptosis-inducer with ATP-competitive mTOR kinase (such as PP242) or dual mTOR/PI3K (such as NVP-BEZ235) may be a new strategy for treating RCC.